Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis
Digestive Diseases · 2024
DOI: 10.1159/000541293 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Digestive Diseases, 2024. Verfasst von Shinyoung Ju und 4 weiteren Autor:innen. Beteiligte Einrichtung: Value Evidence and Outcomes, GSK plc, Brentford, UK. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Health Care Costs, Health Resources, Patient Acceptance of Health Care. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Data on the economic burden of chronic hepatitis B infection in Japan are lacking. This study investigated healthcare resource utilization and costs of chronic hepatitis B infection and liver complications in Japan.
Methods
This non-interventional study used the Medical Data Vision database. For the first analysis, a population with prevalent chronic hepatitis B infection and absence of liver complications was identified and further stratified by nucleos(t)ide analog treatment history. In the second analysis, patients with prevalent chronic hepatitis B infection and incident liver complications were identified. Patients were followed for 1 year in the first analysis and 2 years in the second analysis. Numbers of all-cause outpatient, inpatient, emergency hospitalizations, medication use, and associated costs per person-year were described across patients without/with nucleos(t)ide analog treatment and in those without/with liver complications.
Results
For patients with chronic hepatitis B infection, 75,967 had no liver complications while 17,678 patients had liver complications. All-cause outpatient visits were the largest contributor to healthcare resource utilization and costs, for patients without and with liver complications, and were numerically higher for patients on nucleos(t)ide analog than not. Patients with liver complications had numerically higher all-cause healthcare resource utilization and total costs than patients without complications.
Conclusions
Japan has a high economic burden of chronic hepatitis B infection, particularly in patients with liver complications. Optimizing treatment to prevent complications may reduce this burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Value Evidence and Outcomes, GSK plc, Brentford, UK.
- Value Evidence and Outcomes, GSK K.K., Tokyo, Japan.
- Department of Health Outcomes, Policy, and Economics, Rutgers University, Piscataway, New Jersey, USA.
Zitieren
APA
Ju, S., Katsumata, M., Mizukami, A., Abersone, I., & Gielen, V. (2024). Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis. Digestive Diseases. https://doi.org/10.1159/000541293
Vancouver
Ju S, Katsumata M, Mizukami A, Abersone I, Gielen V. Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis. Digestive Diseases. 2024. doi:10.1159/000541293
BibTeX
@article{Ju2024,
author = {Ju, Shinyoung and Katsumata, Masayuki and Mizukami, Akiko and Abersone, Ilze and Gielen, Vera},
title = {Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis},
journal = {Digestive Diseases},
year = {2024},
doi = {10.1159/000541293}
}
EUVIMED